by sfrazee | Apr 12, 2024
By Tomas J. Philipson April 12, 2024 In their April 9 op-ed, “Big Pharma’s high prices don’t drive innovation,” Avik Roy and Gregg Girvan argued that Medicare’s new authority to demand lower prices from drug manufacturers will not result in the development and...
by sfrazee | Mar 21, 2024
By Tomas J. Philipson & Casey B. Mulligan March 21, 2024 Public health frequently trivializes prevention costs, and therefore misjudges the overall effects of disease policies. This month marks the fourth anniversary of the proclamation on March 13, 2020,...
by sfrazee | Mar 15, 2024
By Scott W. Atlas, Steve H. Hanke, Philip G. Kerpen, and Casey B. Mulligan March 2024 Executive Summary This report reviews the major policy errors and lessons learned during the COVID pandemic from a balanced perspective that includes health, economic,...
by sfrazee | Mar 15, 2024
By Tomas Philipson March 15, 2024 As part of its “Strike Force on Unfair and Illegal Pricing,” the White House just doubled down on a December plan to allow the federal government to tear up exclusive patent agreements between innovative drug companies and...